Friday, October 5, 2012

Epothilones in prostate cancer

“ Although taxane-based regimens offer limited survival benefits, patients frequently relapse, and there are no standard regimens beyond progression.
“ Ixabepilone, sagopilone, and patupilone have demonstrated clinical activity and tolerability in phase II CRPC trials. ”
“ CONCLUSION: The epothilones have demonstrated efficacy in CRPC, and ongoing studies will help define their roles in this disease state, including optimal dosing, combination regimens, and clinical biomarkers of response.



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review